Immunome CTO awarded 76,500 options, 38,250 RSUs
Immunome Inc. reported equity awards to Chief Technical Officer Philip Tsai on July 23, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immunome Inc. reported equity awards to Chief Technical Officer Philip Tsai on July 23, 2026. Tsai received 76,500 stock options at a $22.01 exercise price expiring in 2036 and 38,250 RSUs, all vesting over time contingent on his continuous service, bringing reported direct holdings to 81,550 common shares/RSUs.
Insider Trade Summary
Grant/Award: 114,750 shares
Grant/Award
2 txns
Insider
Tsai Philip
Role
Chief Technical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) F2 | 76,500 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 38,250 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 76,500 contracts (Direct);
Common Stock — 81,550 shares (Direct)
Footnotes (2)
- F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
- F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Key Figures
Stock options granted: 76,500
Option exercise price: $22.01 per share
Option expiration date: 2036-07-22
+4 more
7 metrics
Stock options granted
76,500
Employee Stock Option grant to CTO Philip Tsai on July 23, 2026
Option exercise price
$22.01 per share
Exercise price for 76,500 options granted July 23, 2026
Option expiration date
2036-07-22
Expiration date of Employee Stock Option grant
RSUs granted
38,250
Number of RSUs awarded to Philip Tsai on July 23, 2026
Direct holdings after RSU award
81,550
Total Common Stock/RSUs reported as directly owned after July 23, 2026 award
RSU annual vesting tranche
25%
Portion of RSUs vesting each year on grant-date anniversaries, subject to continuous service
Initial option vesting tranche
25%
Portion of options vesting on July 23, 2027, subject to continuous service
Key Terms
restricted stock units ("RSUs"), Employee Stock Option (right to buy), continuous service, vesting date
4 terms
restricted stock units ("RSUs") financial
"Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option (right to buy) financial
"Security title reported as Employee Stock Option (right to buy) with underlying Common Stock."
continuous service financial
"subject to the Reporting Person's continuous service through each such vesting date."
vesting date financial
"shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Immunome (IMNM) grant to CTO Philip Tsai?
Philip Tsai received 76,500 stock options at a $22.01 exercise price and 38,250 RSUs from Immunome. The awards were granted on July 23, 2026 and vest over several years, subject to his continuous service with the company.
What is the vesting schedule for Philip Tsai’s new IMNM stock options?
The options vest 25% on July 23, 2027, with one‑thirty‑sixth of the remaining shares vesting monthly thereafter. All vesting is contingent on Tsai’s continuous service through each applicable vesting date.
How do Philip Tsai’s new IMNM RSUs vest over time?
The 38,250 RSUs vest and settle into Common Stock in 25% increments on each anniversary of the grant date. Each vesting tranche requires Tsai to remain in continuous service through the relevant vesting date.
Were Philip Tsai’s IMNM equity grants made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5‑1 checkbox is not marked as affirmatively adopted, indicating these awards are not reported as executed under a Rule 10b5‑1 trading plan. They are characterized as grant or award acquisitions.
What are the key terms of Philip Tsai’s new IMNM stock options?
Tsai’s options cover 76,500 shares of Common Stock at a $22.01 exercise price and expire on July 22, 2036. Vesting is time‑based, with an initial 25% vesting after one year, then monthly vesting thereafter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates